From Nasdaq: 2024-05-17 11:01:51

In the last three months, 4 analysts shared ratings for CARISMA Therapeutics (NASDAQ:CARM), showing a range of perspectives from bullish to bearish. Recent ratings comparisons reveal evolving sentiments over the past month.
Insights from analysts’ 12-month price targets show an average of $7.75, with a high estimate of $9.00 and a low estimate of $6.00. The current average target represents a 22.5% decrease from the previous target of $10.00.
Analysts have recently taken different actions on CARISMA Therapeutics, including maintaining, lowering, and announcing buy ratings. Understanding these analyst evaluations alongside key financial indicators can provide valuable insights for investors.
CARISMA Therapeutics is a clinical-stage cell therapy company focused on developing immunotherapies for cancer using its unique platform. The company’s market capitalization surpasses industry averages, with positive revenue growth and a strong net margin, though challenges exist in ROE and ROA.
Analyst ratings provide valuable insights into stock performance based on expert analysis of financial data. These ratings can assist investors in making informed decisions, considering factors like growth estimates and company financial statements. Analysts offer perspectives that can guide investment strategies.

Read more at Nasdaq.: The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts